How Has the Antibodies Market Evolved Historically and What is its Current Size?
The antibodies market has seen considerable growth due to a variety of factors.
• In recent times, the antibodies market has experienced substantial expansion. It's projected to escalate from $286.81 billion in 2024 to $331.01 billion in 2025, signifying a compound annual growth rate (CAGR) of 15.4%.
Factors contributing to this growth in the historical period include an increase in chronic diseases prevalence, a higher number of clinical trials, widening of therapeutic areas, surge in personalized medicine awareness, and an increase in diagnostic applications.
What Does Future Hold for The Antibodies Template Market?
The antibodies market is expected to maintain its strong growth trajectory in upcoming years.
• Over the next few years, the antibodies market is projected to experience substantial growth. The market size is forecasted to inflate to $580.61 billion in 2029, with a compound annual growth rate (CAGR) of 15.1%.
This anticipated growth can be attributed to various factors including the escalation in cancer research, the expansion of immunotherapy applications, the rising usage of monoclonal antibodies, an increase in clinical trials, and the growing embrace of precision medicine. Notable trends for the forecast period include the introduction of sophisticated biomanufacturing technologies, advancements in the field of antibody engineering, the incorporation of high throughput screening methods, the application of next-generation sequencing technologies, and novel delivery systems.
What Are The Leading Drivers Of Growth In The Antibodies Market?
The increase in the occurrence of autoimmune disorders is anticipated to stimulate the expansion of the antibodies market. Autoimmune diseases involve situations where the body's own defense system inaccurately inflicts harm on its tissues, including illnesses such as rheumatoid arthritis, lupus, and multiple sclerosis. The escalating occurrence of these diseases is credited to environmental influences, genetic predisposition, and modifications in lifestyle habits. Antibodies serve to identify and nullify certain immune cells or inflammatory substances that erroneously assault the body's tissues, thus lessening inflammation and easing symptoms. For example, in May 2024, the Multiple Sclerosis International Federation, located in the UK, stated that the worldwide number of people suffering from multiple sclerosis had risen from 2.8 million in 2020 to 2.9 million in 2023. Hence, the mounting prevalence of autoimmune disorders fuels the progress of the antibodies market.
What Is The Segmentation Of The Global Antibodies Market?
The antibodiesmarket covered in this report is segmented –
1) By Product Type: Monoclonal Antibodies, Polyclonal Antibodies, Antibody Drug Complexes
2) By Disease Indication: Cardiovascular Diseases, Central Nervous System (CNS) Disorders, Cancer, Autoimmune Disorders, Other Indications
3) By End User: Hospitals, Long Term Care Facilities, Research Institutes, Other End Users
Subsegments:
1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies, IgA Monoclonal Antibodies, Other Isotypes
2) By Polyclonal Antibodies: Serum-derived Polyclonal Antibodies, Purified Polyclonal Antibodies, Antibody Fractionation Products
3) By Antibody Drug Complexes: Conjugated Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
Pre-Book The Antibodies Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The Antibodies Market Landscape?
Predominant firms in the antibodies market are advancing in the creation of validated antibodies to improve precision and guarantee dependable results in diagnostics and therapeutics. These validated antibodies are ones that have undergone stringent testing and validation to ensure their accuracy and specificity in identifying target proteins, bolstering the reliability of research outcomes, and maintaining the high-quality and effectiveness of antibody-oriented products. For example, Bio-Rad Laboratories, a leader in life science research and clinical diagnostics from the US, introduced Celselect slides validated antibodies for counting rare cells and circulating tumor cells (CTC) in March 2024. This development enhances the exploration of tumor diversity and the progress of diseases. The antibodies, which are fully compatible with Bio-Rad’s Celselect Slides Enumeration Stain Kits, facilitate exact CTC identification and symbolize a major progression in supporting advanced cancer research and diagnosis.
Who Are the Key Players In The Antibodies Market?
Major companies operating in the antibodies market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Merck & Co Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol Myers Squibb Company
• Novartis AG
• GSK plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Alexion Pharmaceuticals Inc.Incyte Corporation
• Kyowa Kirin Co Ltd.
• Ultragenyx Pharmaceutical Inc.
• Xencor Inc.
• MacroGenics Inc.
• ImmunoGen Inc.
• Sorrento Therapeutics Inc.
• Beam Therapeutics Inc.
• SAB Biotherapeutics Inc.
• bluebird bio Inc.
• Iovance Biotherapeutics Inc.
What Are The Regional Insights Into The Antibodies Market?
North America was the largest region in the antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
